Please assess the completion status of the following clinical trial:

Trial Title: Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria include:~* Subjects having IDA caused by different aetiologies~* Haemoglobin (Hb) ≤ 11 g/dL~* Body weight \> 50 kg~* Serum ferritin (S-ferritin) \< 100 ng/mL~* Estimated Glomerular Filtration Rate (eGFR) ≥ 65 mL/min/1.73 m2~* Serum phosphate (S-phosphate) \> 2.5 mg/dL~* Intolerance or unresponsiveness to oral iron~* Willingness to participate and signing the Informed Consent Form (ICF)~Exclusion criteria include:~* Acute bleeding \> 500 mL within 72 hours~* Anaemia predominantly caused by factors other than IDA~* Hemochromatosis or other iron storage disorders~* Previous serious hypersensitivity reactions to any IV iron compounds~* Treatment with IV iron within the last 30 days prior to screening~* Treatment with erythropoietin or erythropoietin-stimulation agents~* Red blood cell transfusion, radiotherapy, and/or chemotherapy~* Received an investigational drug within the last 30 days prior to screening~* Planned surgical procedure within the trial period~* Hepatic enzymes \> 3 times upper limit of normal~* Surgery under anaesthetic within the last 30 days prior to screening~* Any non-viral infection within the last 30 days prior to screening~* Alcohol or drug abuse within the past 6 months~* Vitamin D deficiency~* Untreated hyperparathyroidism~* Kidney transplantation~* Active malignant disease, disease-free for less than 5 years~* History of a psychological illness or seizures~* Pregnant or nursing women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iron isomaltoside/ferric derisomaltose (Type: EXPERIMENTAL): Administered IV
- Ferric carboxymaltose (Type: ACTIVE_COMPARATOR): Administered IV

Based on this trial design, predict the completion outcome and termination type (if applicable).